Large scale sequencing efforts have identified several potentially actionable targets in gastric cancer [3,4], but so far, only trastuzumab, which targets HER2 has been widely approved and used in gastro-oesophageal cancer (GOC) overexpressing HER2. Here, ERBB2 is linked to gastric cancer.